within Pharmacolibrary.Drugs.ATC.C;

model C02KN01
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.6,
    Cl             = 5e-05,
    adminDuration  = 600,
    adminMass      = 25 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005,
    Tlag           = 15.0,            
    Vdp             = 0.06,
    k12             = 7,
    k21             = 7
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>C02KN01</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Aprocitentan is a dual endothelin receptor antagonist developed for the treatment of resistant hypertension. It blocks both ETA and ETB receptors, mediating vasodilation and reduction of blood pressure. As of 2024, aprocitentan is approved in select regions for the management of resistant hypertension.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were estimated for healthy adult volunteers after oral administration.</p><h4>References</h4><ol><li><p>Sidharta, PN, &amp; Dingemanse, J (2020). Effects of Multiple-Dose Administration of Aprocitentan on the Pharmacokinetics of Rosuvastatin. <i>Clinical pharmacology in drug development</i> 9(8) 995–1002. DOI:<a href=\"https://doi.org/10.1002/cpdd.815\">10.1002/cpdd.815</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32592633/\">https://pubmed.ncbi.nlm.nih.gov/32592633</a></p></li><li><p>Fontes, MSC, et al., &amp; Sidharta, PN (2022). Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment. <i>Scientific reports</i> 12(1) 19067–None. DOI:<a href=\"https://doi.org/10.1038/s41598-022-22470-z\">10.1038/s41598-022-22470-z</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/36352054/\">https://pubmed.ncbi.nlm.nih.gov/36352054</a></p></li><li><p>Sidharta, PN, &amp; Dingemanse, J (2020). Effect of Multiple-Dose Aprocitentan Administration on the Pharmacokinetics of Midazolam in Healthy Male Subjects. <i>European journal of drug metabolism and pharmacokinetics</i> 45(2) 227–234. DOI:<a href=\"https://doi.org/10.1007/s13318-019-00590-8\">10.1007/s13318-019-00590-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31773427/\">https://pubmed.ncbi.nlm.nih.gov/31773427</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end C02KN01;
